GSK
GSK expands apprenticeship programme
March 13, 2012Manufacturing and Production, Research and Development GSK, Hayes, R&D, manufacturing
GlaxoSmithKline has expanded its apprenticeship programme with the creation of positions spanning manufacturing, IT, and R&D. The multi-disciplinary scheme is …
Can Europe really agree to speed up pricing and reimbursement?
March 6, 2012Sales and Marketing Europe, European Commission, GSK, Sir Andrew Witty, pricing and reimbursement
The European Commission has called for faster decisions to allow new medicines to enter the market faster.The Commission says the …
GSK collaborates with Dundee on neglected diseases
March 6, 2012Research and Development, Sales and Marketing Africa, Dundee, GSK, Gates, Wellcome
GlaxoSmithKline has teamed up with Dundee University and the Wellcome Trust to develop new drugs for neglected diseases. Healthcare charity …
GSK recalls Novartis’ blood pressure drug
February 28, 2012Manufacturing and Production DynaCirc CR, GSK, Novartis
GlaxoSmithKline is the latest company to be affected by manufacturing glitches at Novartis’ troubled facility in Lincoln, Nebraska, having been …
Witty hits out at ‘systematic delays’ to medicines
February 27, 2012Sales and Marketing Europe, GSK, NICE, austerity
GlaxoSmithKline’s chief executive says Europe’s drug budget cuts are undermining the industry and not addressing the biggest cost pressure in …
GSK pulls Tyverb extension in Europe
February 17, 2012Sales and Marketing GSK, Herceptin, Tyverb, Xeloda
GlaxoSmithKline has withdrawn its European application to extend the licence of its breast cancer pill Tyverb. The firm was seeking …
Emerging markets no haven from HTA, says NICE
February 15, 2012Andrew Witty, GSK, NICE, NICE International
The head of NICE says pharma will face health technology assessment barriers in every country – including fast-growing developing markets. …
NICE cannot recommend breast cancer drugs
February 14, 2012Sales and Marketing GSK, Herceptin, NHS, NICE, Roche, Tyverb
NICE is not recommending GlaxoSmithKline’s Tyverb or Roche’s Herceptin for use in certain breast cancer patients. The watchdog said in …
GSK posts strong underlying sales growth
February 8, 2012Research and Development, Sales and Marketing Avodart, GSK, R&D, Seretide, Witty, rotarix
GlaxoSmithKline has posted strong underlying growth for 2011, but warns of a tough year ahead. The UK firm saw 4% …
James Murdoch steps down from GSK board
January 27, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, James Murdoch
GlaxoSmithKline has announced that after nine years with the firm, Sir Crispin Davis, Sir Robert Wilson and Larry Culp will …
Underwhelming results for GSK’s Relovair
January 10, 2012Research and Development, Sales and Marketing Advair, COPD, GSK, Relovair, Seretide, asthma
GlaxoSmithKline says it is on track to file its respiratory drug Relovair in Europe and the US despite mixed results …
GSK faces fine over Argentina clinical trial
January 6, 2012Research and Development, Sales and Marketing Argentina, GSK, Vaccine, deaths, emerging markets
A court in Argentina says GSK should be fined for irregularities in recruitment during a trial in which children died. …
GSK’s Andrew Witty knighted
January 3, 2012Sales and Marketing Andrew Witty, GSK
GlaxoSmithKline chief executive Andrew Witty and former ABPI director general Richard Barker were among the recipients in the 2012 New …
GSK sells off over-the-counter brands
December 22, 2011Sales and Marketing GSK, OTC
GlaxoSmithKline has offloaded a number of OTC consumer health brands in North America for £426 million in cash. Flagged up …
GSK’s Stiefel accused of shares fraud
December 13, 2011Sales and Marketing GSK, SEC, Stiefel, fraud
The US financial regulator has charged a subsidiary of GlaxoSmithKline with defrauding staff by buying back shares from them at …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
